Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Clinical Genomic Analyses Demonstrate t(11;14) Multiple Myeloma Retains B-Cell Biology and Distinct Mitochondrial Metabolism That Convey Increased Sensitivity to BCL-2 Inhibition By Venetoclax
Dunbar, Fengjiao, Wang, Xifeng , Li, Xiaotong , Mantis, Christine, Bueno, Orlando F. , Kumar, Shaji , Epling-Burnette, PK, Sharon, David M. , Jung, Paul , Touzeau, Cyrille , Moreau, Philippe , Harrison, Simon J , Costa, Luciano J. , Kaufman, Jonathan L. , Bahlis, Nizar Jacques , Ross, Jeremy A.

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 4242-4244

10.1182/blood-2022-160195 Get It

Longitudinal Single Cell Multiomic Analysis of a Patient with GATA2 Haploinsufficiency with ASXL1 Mutant Clonal Hematopoiesis
Mudappathi, Rekha , Finke, Christy M. , Gangat, Naseema , Abraham, Roshini S. , Mangaonkar, Abhishek A. , Patnaik, Mrinal M. , Ferrer, Alejandro , Lasho, Terra L. , Carr, Ryan M , Fernandez, Jenna , Binder, Moritz , Wang, Junwen

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 8672-8673

10.1182/blood-2022-167808 Get It

Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Fathi, Amir T. , Issa, Ghayas C., Altman, Jessica K. , Montesinos, Pau , Patnaik, Mrinal M. , Foran, James M. , Baer, Maria R. , Schiller, Gary J. , Walter, Roland B. , Kremyanskaya, Marina , Pettit, Kristen , Tomkinson, Blake, Tabachri, Marilyn, Leoni, Mollie , Dale, Stephen , Montesinos, Pau , Walter, Roland B , Pettit, Kristen , Erba, Harry Paul , Issa, Ghayas , Botton, Stéphane de , Strickland, Stephen Anthony , Wang, Eunice S.

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 153-156

10.1182/blood-2022-167412 Get It

Advances in Cardiac Electrophysiology
Piccini, Jonathan P. , Russo, Andrea M. , Sharma, Parikshit S. , Kron, Jordana , Tzou, Wendy S. , Sauer, William H. , Park, David , Birgersdotter‐Green, Ulrika , Frankel, David S. , Healey, Jeff S. , Linz, Dominik , Wißner, Erik , Zeitler, Emily P. , Wang, Paul J. , Tzou, Wendy , Park, David S , Hummel, John , Koruth, Jacob , Linz, Dominik , Mittal, Suneet , Nair, Devi G , Nattel, Stanley , Noseworthy, Peter A , Steinberg, Benjamin A , Trayanova, Natalia A , Wan, Elaine Y , Wissner, Erik , Zeitler, Emily P , Wang, Paul J , Healey, Jeffrey S , Hummel, John D. , Noseworthy, Peter A. , Steinberg, Benjamin A. , Trayanova, Natalia A. , Wan, Elaine Y.

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | November 28, 2022 | Volume: 15 | Issue: 12 | Pages: No page available

10.1161/circep.121.009911 | PMID 36441565 Get It

Despite the global COVID-19 pandemic, during the past 2 years, there have been numerous advances in our understanding of arrhythmia mechanisms and diagnosis and in new therapies. We increased our understanding of risk factors and mechanisms of atrial arrhythmias, the prediction of atrial arrhythmias, response to treatment, and outcomes using machine learning and artificial intelligence. There have been new technologies and techniques for atrial fibrillation ablation, including pulsed field ablation. There have been new randomized trials in atrial fibrillation ablation, giving insight about rhythm control, and long-term outcomes. There have been advances in our understanding of treatment of inherited disorders such as catecholaminergic polymorphic ventricular tachycardia. We have gained new insights into the recurrence of ventricular arrhythmias in the setting of various conditions such as myocarditis and inherited cardiomyopathic disorders. Novel computational approaches may help predict occurrence of ventricular arrhythmias and localize arrhythmias to guide ablation. There are further advances in our understanding of noninvasive radiotherapy. We have increased our understanding of the role of His bundle pacing and left bundle branch area pacing to maintain synchronous ventricular activation. There have also been significant advances in the defibrillators, cardiac resynchronization therapy, remote monitoring, and infection prevention. There have been advances in our understanding of the pathways and mechanisms involved in atrial and ventricular arrhythmogenesis.
Liquid Chromatography–Tandem Mass Spectrometry in Newborn Screening Laboratories
Basheeruddin, Khaja, Burlina, Alberto , Chen, Hsiao-Jan, Dizikes, George J. , Dorley, M. Christine , Giugliani, Roberto , Hietala, Amy, Kao, Shu‐Min, Klug, Tracy, Kubaski, Francyne , Liao, Hsuan-Chieh , Martin, Monica, Manning, Adrienne, Orsini, Joseph J. , Peng, Yin , Ranieri, Enzo , Rohrwasser, Andreas , Szabo‐Fresnais, Nicolas, Turgeon, Coleman , Wang, Liyun , Matern, Dietrich , Burlina, Alberto , Chien, Yin-Hsiu , Dorley, Christine , Giugliani, Roberto , Kubaski, Francyne , Turgeon, Coleman T, Matern, Dietrich , Gelb, Michael H. , Hong, Xinying , Khaledi, Hamid , Vaz, F

Mayo Clinic

International Journal of Neonatal Screening | November 28, 2022 | Volume: 8 | Issue: 4 | Pages: 62

10.3390/ijns8040062 | PMID 36547379 Get It

Tandem mass spectrometry (MS/MS) is the most universal platform currently available for the analysis of enzymatic activities and biomarkers in dried blood spots (DBS) for applications in newborn screening (NBS). Among the MS/MS applications in NBS, the most common is flow-injection analysis (FIA-) MS/MS, where the sample is introduced as a bolus injection into the mass spectrometer without the prior fractionation of analytes. Liquid chromatography combined with MS/MS (LC-MS/MS) has been employed for second-tier tests to reduce the false-positive rate associated with several nonspecific screening markers, beginning two decades ago. More recently, LC-MS/MS has been applied to primary screening for new conditions for which FIA-MS/MS or other methods, including genomic screening, are not yet adequate. In addition to providing a list of the currently used LC-MS/MS-based assays for NBS, the authors share their experience regarding the maintenance requirements of LC-MS/MS vs. FIA-MS/MS systems. The consensus is that the maintenance of LC-MS/MS and FIA-MS/MS instrumentation is similar, and LC-MS/MS has the advantage of allowing for a larger number of diseases to be screened for in a multiplex, cost-effective fashion with a high throughput and an adequate turnaround time.
Body mass index and molecular subtypes of colorectal cancer
Murphy, Neil , Newton, Christina C. , Papadimitriou, Nikos , Hoffmeister, Michael , Phipps, Amanda I. , Harrison, Tabitha A. , Aglago, Elom K. , Berndt, Sonja I. , Brenner, Hermann , Cao, Yin , Chang‐Claude, Jenny , French, Amy J. , Gallinger, Steven , Georgeson, Peter , Giannakis, Marios , Gruber, Stephen B. , Harlid, Sophia , Huang, Wen‐Yi , Laskar, Ruhina Shirin , Mandic, Marko , Nowak, Johnathan A., Obón‐Santacana, Mireia , Steinfelder, Robert S. , Thibodeau, Stephen N. , Trinh, Quang M. , Tsilidis, Kostas K, Guelpen, Bethany Van , Wang, Xiaoliang , Woods, Michael O. , Zaidi, Syed Hassan Ejaz , Gunter, Marc J. , Peters, Ulrike , Song, Mingyang , Song, Mingyang , Hoffmeister, Michael , Harrison, Tabitha A , Brenner, Hermann , Cao, Yin , Chen, Xuechen , Drew, David A , Harlid, Sophia , Huang, Wen-Yi , Marchand, Loïc Le , Limburg, Paul, Sun, Wei , Ugai, Tomotaka , Van Guelpen, Bethany , Wang, Xiaoliang , Woods, Michael O , Gunter, Marc J , Murphy, Neil , Song, Mingyang , Aglago, Elom K , Obón-Santacana, Mireia , Papadimitriou, Nikos , Mandic, Marko , Trinh, Quang M , Georgeson, Peter , Newcomb, Polly A. , Buchanan, Daniel D. , Chan, Andrew T. , Cheng, Iona C. , Dimou, Niki , Drew, David A. , Farris, Alton B. , Giles, Graham G. , Hsu, Li , Jenkins, Mark A. , Marchand, Loı̈c Le , Limburg, Paul J. , Lin, Yi , Ogino, Shuji , Qu, Conghui , Sakoda, Lori C. , Schoen, Robert E. , Southey, Melissa C. , Stadler, Zsofia , Sun, Wei , Toland, Amanda Ewart , Tsilidis, Kostas K, Campbell, Peter T.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | November 26, 2022 | Volume: 115 | Issue: 2 | Pages: 165-173

10.1093/jnci/djac215 | PMID 36445035 Get It

Abstract Background Obesity is an established risk factor for colorectal cancer (CRC), but the evidence for the association is inconsistent across molecular subtypes of the disease. Methods We pooled data on body mass index (BMI), tumor microsatellite instability status, CpG island methylator phenotype status, BRAF and KRAS mutations, and Jass classification types for 11 872 CRC cases and 11 013 controls from 11 observational studies. We used multinomial logistic regression to estimate odds ratios (OR) and 95% confidence intervals (CI) adjusted for covariables. Results Higher BMI was associated with increased CRC risk (OR per 5 kg/m2 = 1.18, 95% CI = 1.15 to 1.22). The positive association was stronger for men than women but similar across tumor subtypes defined by individual molecular markers. In analyses by Jass type, higher BMI was associated with elevated CRC risk for types 1-4 cases but not for type 5 CRC cases (considered familial-like/Lynch syndrome microsatellite instability-H, CpG island methylator phenotype-low or negative, BRAF-wild type, KRAS-wild type, OR = 1.04, 95% CI = 0.90 to 1.20). This pattern of associations for BMI and Jass types was consistent by sex and design of contributing studies (cohort or case-control). Conclusions In contrast to previous reports with fewer study participants, we found limited evidence of heterogeneity for the association between BMI and CRC risk according to molecular subtype, suggesting that obesity influences nearly all major pathways involved in colorectal carcinogenesis. The null association observed for the Jass type 5 suggests that BMI is not a risk factor for the development of CRC for individuals with Lynch syndrome.
Disparities in the Inclusion of Racial and Ethnic Minority Groups and Older Adults in Prostate Cancer Clinical Trials
Islam, Mahnoor, Ikram, Waleed, Naqvi, Syed Arsalan Ahmed , Riaz, Anum, Ravi, Praful , Odedina, Folakemi T., Duma, Narjust , Kehl, Kenneth L. , Kamran, Sophia C. , Bryce, Alan H. , Singh, Parminder , Riaz, Irbaz Bin , Murad, Mohammad Hassan, Bryce, Alan Haruo, Bryce, Alan H , Singh, Parminder , Maqsood, Hamza , Saleem, Yusra, Wang, Zhen , Hussain, Syed A. , Warner, Jeremy L. , Singh, Parminder Pal , Murad, M. Hassan , Landman, Adam , Van Allen, Eliezer M

Mayo Clinic

JAMA Oncology | November 23, 2022 | Volume: 9 | Issue: 2 | Pages: 180

10.1001/jamaoncol.2022.5511 | PMID 36416812 Get It

ImportanceProstate cancer (PCa) is marked by disparities in clinical outcomes by race, ethnicity, and age. Equitable enrollment in clinical trials is fundamental to promoting health equity.ObjectiveTo evaluate disparities in the inclusion of racial and ethnic minority groups and older adults across PCa clinical trials.Data SourcesMEDLINE, Embase, and ClinicalTrials.gov were searched to identify primary trial reports from each database's inception through February 2021. Global incidence in age subgroups and US population-based incidence in racial and ethnic subgroups were acquired from the Global Burden of Disease and Surveillance, Epidemiology, and End Results 21 incidence databases respectively.Study SelectionAll phase 2/3 randomized PCa clinical trials were eligible for age disparity analyses. Trials recruiting exclusively from the US were eligible for primary racial and ethnic disparity analyses.Data Extraction and SynthesisThis study was reported in accordance with Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guidelines. Data were pooled using a random-effects model.Main Outcomes and MeasuresEnrollment incidence ratios (EIRs), trial proportions (TPs) of participants 65 years or older or members of a racial and ethnic subgroup divided by global incidence in the corresponding age group, or US population–based incidence in the corresponding racial and ethnic subgroup, were calculated. Meta-regression was used to explore associations between trial characteristics and EIRs and trends in EIRs during the past 3 decades.ResultsOf 9552 participants among trials reporting race, 954 (10.8%) were African American/Black, 80 (1.5%) were Asian/Pacific Islander, and 8518 (78.5) were White. Of 65 US trials, 45 (69.2%) reported race and only 9 (13.8%) reported data on all 5 US racial categories. Of 286 global trials, 75 (26.2%) reported the enrollment proportion of older adults. Outcomes by race and age were reported in 2 (3.1%) and 41 (15.0%) trials, respectively. Black (EIR, 0.70; 95% CI, 0.59-0.83) and Hispanic (EIR, 0.70; 95% CI, 0.59-0.83) patients were significantly underrepresented in US trials. There was no disparity in older adult representation (TP, 21 143 [71.1%]; EIR, 1.00; 95% CI, 0.95-1.05). The representation of Black patients was lower in larger trials (meta-regression coefficient, −0.06; 95% CI, −0.10 to −0.02; P = .002).Conclusions and RelevanceThe results of this meta-analysis suggest that Black and Hispanic men are underrepresented in trials compared with their share of PCa incidence. The representation of Black patients has consistently remained low during the past 2 decades.